Oraclebio: Ultivue and OracleBio partner to help advance personalized tumor characterization and clinical oncology research using multiplex immunofluorescence

CAMBRIDGE, Mass.-(BUSINESS WIRE)-Ultivue, Inc. today announced a collaborative partnership with OracleBio to help further insights and advance personalized tumor characterization in translational and clinical oncology research and drug development using multiplex immunofluorescence staining and imaging. The deal connects the histopathology image analysis expertise of OracleBio and the tissue staining capabilities of Ultivue, with the goal [...]The post Ultivue and OracleBio partner to help advance personalized tumor characterization and clinical oncology research using multiplex immunofluorescence appeared first on Drug Genius.